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Abstract
Background: Previously we have shown that oncogenic Ha-Ras stimulated in vivo metastasis through RalGEF-Ral
signaling. RalA and RalB are highly homologous small G proteins belonging to Ras superfamily. They can be
activated by Ras-RalGEF signaling pathway and influence cellular growth and survival, motility, vesicular transport
and tumor progression in humans and in animal models. Here we first time compared the influence of RalA and
RalB on tumorigenic, invasive and metastatic properties of RSV transformed hamster fibroblasts.
Methods: Retroviral vectors encoding activated forms or effector mutants of RalA or RalB proteins were introduced
into the low metastatic HET-SR cell line. Tumor growth and spontaneous metastatic activity (SMA) were evaluated
on immunocompetent hamsters after subcutaneous injection of cells. The biological properties of cells, including
proliferation, clonogenicity, migration and invasion were determined using MTT, wound healing, colony formation
and Boyden chamber assays respectively. Protein expression and phosphorylation was detected by Westen blot
analysis. Extracellular proteinases activity was assessed by substrate-specific zymography.
Results: We have showed that although both Ral proteins stimulated SMA, RalB was more effective in metastasis
stimulation in vivo as well as in potentiating of directed movement and invasion in vitro. Simultaneous expression
of active RalA and RalB didn’t give synergetic effect on metastasis formation. RalB activity decreased expression of
Caveolin-1, while active RalA stimulated MMP-1 and uPA proteolytic activity, as well as CD24 expression. Both Ral
proteins were capable of Cyclin D1 upregulation, JNK1 kinase activation, and stimulation of colony growth and
motility. Among three main RalB effectors (RalBP1, exocyst complex and PLD1), PLD1 was essential for RalB-
dependent metastasis stimulation.
Conclusions: Presented results are the first data on direct comparison of RalA and RalB impact as well as of
RalA/RalB simultaneous expression influence on in vivo cell metastatic activity. We showed that RalB activation
significantly more than RalA stimulates SMA. This property correlates with the ability of RalB to stimulate in vitro
invasion and serum directed cell movement. We also found that RalB-PLD1 interaction is necessary for the
acquisition of RalB-dependent high metastatic cell phenotype. These findings contribute to the identification of
molecular mechanisms of metastasis and tumor progression.
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Metastatic spread of primary tumors is a major determi-
nant of cancer-related death. Metastatic process involves
multiple steps including local tumor cells dissemination,
survival in blood circulation, arrest in vasculature, extra-
vasation and growth in distant organs and tissues [1].
Investigation of signaling pathways regulating metastasis
and associated gene expression changes is an important
step for designing therapeutic strategies.
Small G proteins RalA and RalB belong to Ras super-
family [2] and are implicated in tumorigenesis, invasion
and metastasis [3-7]. RalA and RalB share 82% amino
acid identity [8] and participate in numerous cellular
processes such as endocytosis, exocytosis, actin reorga-
nization and cell motility, proliferation and modulation
of cancer-associated genes expression (for review see
[9]). Like all GTPases Ral proteins cycle between active
GTP- and inactive GDP-bound states. Ral can bind to
and regulate activity of various proteins including Ral
binding protein-1 (RalBP1, RLIP76) [10], phospholipase
D1 (PLD1) [11], filamin A [12], exocyst subunits Sec5
and Exo84 [13]. Although RalA and RalB have almost
identical effector-binding domains, these two proteins
may preferentially utilize different effectors [14].
Ral proteins are activated by RalGEFs, some of which
are Ras effectors (i.e. RalGDS, Rgl1, Rgl2). Oncogenic
Ras mutations were found in subset of human tumors
and cell lines. RalA and RalB were shown to be activated
in pancreatic cancers, aggressive malignancies with high
frequency of Ras mutations [15]. It was shown that RalA
and RalB were necessary for acquisition of aggressive
cellular phenotype in diverse models of tumor progres-
sion. Ral proteins were capable to stimulate prostate
cancer metastasis to bone. Suppression of RalB activity
led to decrease of oncogenic Ras-mediated invasion in
vitro and reduced metastasis after prostate cancer cells
intracardiac injection [16]. Ral GTPases also mediated
progression of bladder cancer in animal models [17].
However, little emphasis has been made on comparison
of individual roles of RalA and RalB and their down-
stream partners in tumor progression.
Here we compared the influence of constitutively
active RalA and RalB expression on tumor progression.
We showed that both active Ral proteins enhanced
spontaneous metastatic activity (SMA) of HET-SR cells,
however RalB was more potent in stimulation of lung
colonization, as well as in promotion of cell invasion
and directed migration. SMA stimulating effect depends
on N-terminus of RalB protein, which is known to be
critical for RalB-PLD1 interaction. We also found RalA-
dependent increase of extracellular matrix proteinases
activity and RalA/B mediated metastasis-associated sig-
naling cascades stimulation.
Results
RalB is more potent in metastasis stimulation than RalA
Previously we have shown that introduction of oncogenic
Ha-Ras stimulated spontaneous metastatic activity of
RSV-transformed hamster embryo fibroblasts (HET-SR
cell line) through activation of RalGDS signaling pathway.
Overexpression of active RalA also enhanced lung metas-
tasis formation in immunocompetent hamsters [18].
Here we compared the ability of RalA and RalB to influ-
ence metastatic potential and associated properties of
tumorigenic low-metastatic HET-SR cell line. For this pur-
pose we generated stable cell lines HET-SR-RalA and
HET-SR-RalB expressing active GTP-bound forms of Ral
proteins (RalA G23V and RalB G23V) in retroviral vectors
(pLXSN and pBabe-puro, respectively). Expression of exo-
genous Ral proteins was confirmed by Western blot analy-
sis of total cell populations selected on G-418 (HET-SR-
RalA) or puromycin (HET-SR-RalB) (Figure 1a).
For evaluation of SMA, 10
4 cells of HET-SR-RalA or
HET-SR-RalB in parallel with cell lines expressing
empty vectors were subcutaneously injected into 10
immunocompetent syngeneic animals. Two months
later tumor-bearing hamsters were sacrificed; paraffin-
embedded lungs were step-sectioned and stained with
hematoxylin-eosin (Figure 1b). Metastatic lesions in
lungs were counted microscopically. We found statisti-
cally significant increase in metastatic nodules number
per animal (in comparison with empty vector-expressing
cells) for both cell lines (Figure 1c). RalB-dependent sti-
mulation of SMA was noticeably higher: cells expressing
active RalB formed 63.7 ± 19, while HET-SR-RalA
formed 20 ± 4 lung nodules per animal in comparison
w i t h7±1 . 9a n d4±2n o d u l e sf o r m e db yc e l ll i n e s
bearing empty vectors, HET-SR-pBabe and HET-SR-
pLXSN respectively. Therefore, RalB effect on metas-
tases stimulation was 3 times more than RalA.
Simultaneous expression of active Ral proteins has no
additive effect on metastasis
It was previously shown that RalA and RalB proteins
may have non-overlapping or even opposite influence
on several cellular properties [4,6,19-21]. At the same
t i m et h e r ew e r en od a t ac o n c e r n i n ge f f e c to fs i m u l t a -
neous expression of active RalA and RalB on metastasis.
To test whether Ral proteins cooperate in SMA stimula-
tion we introduced active RalB in retroviral vector
pBabe-puro (or pBabe-puro vector alone as a control)
into HET-SR-RalA cells. The expression of RalB in
derived HET-SR-RalA-RalB cells was confirmed by wes-
tern blot analysis (Figure 1d). SMA assay revealed that
HET-SR-RalA-RalB cell line formed 16.2 ± 1.3 lung
metastatic nodules. This value was comparable to con-
trol HET-SR-RalA-pBabe cells (12.3 ± 3.2) and
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Page 2 of 12considerably less than HET-SR-RalB cells (63.7 ± 19)
(Figure 1e). Therefore we c o n c l u d e dt h a tc o m b i n e d
expression of both Ral proteins doesn’t give an addi-
tional stimulation of SMA compared to the effect of
RalB expression alone. This result gives evidence that
exogenous RalB expression in the presence of exogenous
RalA inhibits original RalB potency of metastasis
stimulation.
Active RalA and RalB similarly modulate cell growth
Aggressive phenotype of transformed cells could be
partly defined by their ability to grow in different
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Figure 1 Ral-dependent stimulation of spontaneous metastatic activity. (a) Expression of exogenous Ral proteins (RalA-G23V in pLXSN
vector (HET-SR-RalA) and RalB-G23V in pBabe vector (HET-SR-RalB)) in HET-SR cell line was confirmed by Western blot analysis using anti RalA or
anti-RalB antibodies followed by quantification. (b) Hematoxylin-eosin staining of control hamster lung and metastatic nodule formed by RalB-
expressing cells (c.) RalB stimulates spontaneous metastatic activity (SMA) more than RalA. Indicated is number of lung metastases formed two
months after subcutaneous injection of cells into adult immunocompetent hamsters; the average for 10 animals is shown with standard error
(SE). (d, e) Simultaneous expression of RalA and RalB doesn’t give additive effect on SMA. (d) Western blot analysis and quantification of RalA/B
expression in HET-SR-RalA-RalB cells obtained by RalB transduction into HET-SR-RalA cells. (e) Graphs represent influence of RalA- and RalA-RalB
combined expression on SMA of HET-SR cells.
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on cell proliferation, we conducted MTT-test on daily
basis for a period of five days. The growth curve of each
cell group did not reveal significant effect of RalA or
RalB on cell proliferation (Figure 2a). These results sug-
gest that both active Ral proteins do not change prolif-
eration dynamics of studied cells in standard culture
conditions.
Next, we studied the influence of Ral proteins on the
ability to grow under conditions of rare population (clo-
nogenicity assay) to reveal possible role of these proteins
in autocrine or paracrine stimulation of cell growth. We
found that both Ral proteins significantly increased the
size of colonies after seeding of 200 cells per 6-cm dish
(p < 0.01) although RalB was more potent. Thus, RalA
expression enlarged colony size 1.9 fold, while RalB gave
2.6 fold increase of this value compared to control cells
(Figure 2b). At the same time, no difference in the num-
ber of colonies formed by all studied cells was detected
(data not shown).
We also tested whether RalA or RalB could stimulate
tumor growth in vivo. For this 2 × 10
3 of control vec-
tors- and RalA- or RalB-expressing HET-SR cells were
injected subcutaneously in adult immunocompetent ani-
mals. Tumor growth was measured starting from the
14
th day after injection (time of measurable tumor
appearance). We did not find significant differences
neither in growth dynamics (data not shown) nor in
tumor size for HET-SR-RalA or HET-SR-RalB cells in
comparison with corresponding controls (Figure 2c).
Ral proteins stimulate cell motility and invasion in vitro
The in vitro invasiveness of Ral-expressing cells towards
serum gradient was examined using Matrigel-coated
Boyden chambers (Millipore). We found that HET-SR-
RalB cells invaded significantly better than HET-SR-
RalA cells, although both RalA- and RalB-expressing
cells were more active in this test than corresponding
control cells (HET-SR-pLXSN and HET-SR-pBabe
respectively) (Figure 3a,b). Therefore, both Ral proteins
stimulate cell invasion but with different potency. This
result is in compliance with Ral-mediated SMA increase
of HET-SR cell line.
The ability to penetrate through Matrigel-coated
membrane depends on ECM remodeling proteinases
activity on the one hand and motility on the other. To
study molecular mechanisms of Ral-dependent stimula-
tion of cell invasion we examined the activity of certain
extracellular proteinases. We studied matrix metallopro-
teinases (MMPs) with gelatinase activity and urokinase-
like plasminogen activator (uPA). These proteinases are
responsible for matrix degradation and thus contribute
to tumor progression and metastasis. The secreted pro-
teinases activity was tested in culture media by casein/
plasminogen (for uPA) or gelatin (for MMPs) zymogra-
phies. MMP-2 was the most active gelatinase secreted
by all studied cells. We didn’t reveal any difference in
MMP-2 and MMP-9 activities between studied cell lines
(Figure 3c). RalA-expressing cells demonstrated 6.3-fold
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Figure 2 Effect of active Ral proteins on HET-SR cells growth
characteristics. (a) Ral proteins expression has no significant
influence on HET-SR cells proliferation.; OD595 absorption in MTT test
is shown as average of three independent experiments ± SE. (b)
RalB is more active than RalA in stimulation of colony formation in
clonogenicity assay. Colonies were measured 6 days after seeding at
low cell density (200 cells per 6-cm dish); colony size is shown in
arbitrary units as average for three independent experiments ± SE.
(c) Neither RalA nor RalB modulate tumorigenicity of HET-SR cells.
Indicated is the size of tumors two months after injection as
average for 10 animals ± SE.
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Figure 3 Migrative and invasive properties of Ral-expressing HET-SR cells. (a,b) RalB is more active in stimulation of in vitro invasion. Invaded
cells were stained with crystal violet 18 hours after seeding on Matrigel-coated Boyden chambers; (a) Representative pictures of three independent
experiments are shown. (b) Graphs correspond to the number of invaded cells shown as average for three independent experiments ± SE. (c)
Gelatin zymography was used to study the activity of matrix metalloproteases (MMPs) in conditioned media. RalA increases MMP-1 proenzyme
level (proMMP-1) and drastically stimulates MMP-1 activity, while RalB has no effect on studied gelatinases. (d) RalA opposite to RalB increases
activity of urokinase-like plasminogen activator (uPA). uPA activity in conditioned media was revealed by casein-plasminogen zymography. (e,f)
Both Ral proteins stimulate cell motility in “wound healing” assay. (e) Representative pictures of wounds at 0 and 24 hours after scratching. (f)
Graphs correspond to migration indexes shown as average for three independent experiments ± SE. (g,h) RalB is more potent in stimulation of
growth factors-directed migration in transwell assay. (g) Migrated cells were stained with hematoxylin-eosin 18 hours after seeding in uncoated
chambers. (h) Graphs correspond to the number of transwell migrated cells shown as average for three independent experiments ± SE.
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control HET-SR-pLXSN cells. In contrast, MMP-1 activ-
ity in HET-SR-RalB cells remained at the same level as
in the control HET-SR-pBabe. Moreover, active form of
MMP-1 was detected only in RalA expressing cells.
Comparison of uPA activity in conditioned media also
revealed its significant (2.8-fold) increase in RalA-
expressing cells (Figure 3d). Therefore, RalB-associated
increase of in vitro invasion is unlikely to be caused by
differences in studied ECM proteinases activity.
We also tested whether Ral-mediated changes in cell
motility could contribute to invasion stimulation. Cells
were subjected to in vitro “wound healing” assay. As
shown in Figures 3e,f, expression of active RalA and
RalB lead to similar increase in “wound healing” effi-
ciency (migration indexes for RalA and RalB were 44%
and 42%, whereas migration indexes for controls were
25% and 27% respectively).
Results obtained on proteinases activity and wound
healing do not explain RalB-mediated increase of inva-
siveness in Matrigel-coated chambers. This increase
could be determined by difference in efficiency of
serum-directed migration. We used migration through
uncoated porous inserts assay to check this possibility.
We found that both RalA- and RalB-overexpressing cells
demonstrated higher levels of transwell migration than
corresponding control cells. Moreover, RalB was signifi-
cantly more active than RalA in promoting directed
migration (Figure 3g,h).
Thereby, we conclude that the difference in Ral-
mediated stimulation of in vitro invasion definitely cor-
related with SMA of studied cells and is most probably
determined by the difference in their ability for chemo-
tactic movement.
Ral proteins regulate CD24, Cav-1, Cyclin D1 and pJNK1
protein expression
Ral influence on intracellular signaling and protein
expression has been intensively investigated. Here we
studied some different branches of metastasis-associated
signaling pathways, potentially regulated by Ral proteins
(Figure 4).
It was previously shown that RalA depletion downre-
gulated cell surface highly-glycosylated protein CD24
expression in bladder cancer cell lines [22]. This mole-
cule may regulate cell survival and proliferation as well
as tumor metastasis. CD24 has been proposed to be a
marker of pancreatic cancer stem cells and may be asso-
ciated with unfavorable prognosis [23]. To test whether
Ral-mediated increase of SMA is associated with
increase of CD24 expression we estimated its level by
Western blotting. We revealed that overexpression of
active RalA but not RalB upregulated CD24 expression
(Figure 4a). This observation suggests that CD24 is
unlikely to be a marker of highly metastatic cell pheno-
type in the studied experimental model.
It was shown that RalB could increase the NF-B-
dependent expression of Cyclin D1 [24]. Cyclin D1 func-
tions as a well-known mitogenic mediator. Recent studies
revealed that Cyclin D1 also acts as a motogen and pro-
motes cell migration [25,26]. We tested Cyclin D1 level
in cells expressing active RalA and RalB and found that
both Ral proteins stimulated expression of this protein in
comparison to the control cells (Figure 4b). At the same
time RalB-dependent increase of CyclinD1 expression
was 2.5 fold higher than in RalA expressing cells. There-
fore, elevation of CyclinD1 level in both RalA and RalB
expressing cells correlates with stimulation of cell moti-
lity. However, RalB influence on CyclinD1 is noticeably
stronger than that of RalA, what correlates with more
pronounced effect of RalB on SMA.
Caveolin-1 (Cav-1) is a structural protein of caveolae,
a special type of lipid rafts that can modulate various
proteins activity e.g. Ras, Cyclin D1, Erk1/2, p38 and
others [27]. Cav-1 downregulation is associated with
aggressiveness of certain tumors and cell lines and it
was previously shown that Cav-1 depletion downregu-
lated RalA expression [28]. We found that overexpres-
sion of active RalB (but not RalA) in HET-SR cells led
to more than 3 fold decrease of Cav-1 (Figure 4c).
Therefore Cav-1 downregulation in studied model cor-
relates with aggressive cell phenotype.
We also studied the influence of Ral activation on
phosphorylation status of three main MAPK kinases:
extracellular signal-regulated kinase (ERK1/2), c-Jun N-
terminal kinase (JNK1), and p38 MAPK. We didn’tf i n d
significant changes neither in ERK1/2 nor in p38 kinase
phosphorylation (Figure 4d,e). At the same time, JNK1
was activated both in RalA- and RalB-overexpressing
cells (Figure 4f).
Stimulation of metastasis by active RalB expression
depends on RalB-PLD interaction
In order to study RalB-downstream signaling and to
reveal RalB partners mainly responsible for metastasis
stimulation, we tested the influence of RalB effector
mutants on spontaneous metastatic activity of HET-SR
cells. Sequences encoding three effector mutants of
active RalB: D49N, D49E (effector loop mutants) and
ΔN11 (11 N-terminal amino-acids deleted) were cloned
into pBabe-puro retroviral vector and stably expressed
in HET-SR cells. These three mutations impeded RalB
interaction with downstream partners RalBP1 [29], Sec5
and Exo84 exocyst subunits [30] and PLD1 respectively
[31]. Expression of RalB mutant proteins was confirmed
by Western blot analysis of total cell lysates after selec-
tion on puromycin (Figure 5a). In vivo analysis of
obtained cell lines (Figure 5b) revealed that both D49N
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0,05) stimulated SMA in comparison to the control vec-
tor. There were no significant differences between SMA
of HET-SR-RalB-D49N and HET-SR-RalB-D49E and
cells expressing fully active RalB G23V. In contrast,
RalB mutant with deletion of 11 N-terminal aminoacids
exhibited low level of SMA, comparable to that of con-
trol cells. So, blocking of RalB-PLD1 interaction
abolishes RalB-dependent metastasis stimulation and
suggests phospholipase D1 to be the main RalB effector
responsible for acquisition of high metastatic phenotype.
Discussion
Molecular pathways regulating tumor metastasis to dis-
tant organs are still poorly understood. Research in this
area is hampered by multiplicity and complexity of steps
and factors involved in this process and by the absence
of criteria determining the metastatic behavior.
Common in vivo models used in different studies are
based either on mouse cell lines or on human cultures
injected into immunocompromised animals. The model
system used here includes HET-SR line that is charac-
terized by high tumorigenicity (minimal subcutaneous
inoculation dose - 200 cells) and low lung specific spon-
taneous metastasis (0-5 metastatic nodules per lung) in
syngeneic immunocompetent animals [32-35].
According to mouse models of tumor progression it
was previously considered that major Ras-downstream
pathways are Raf-MAPK and PI3K signaling cascades.
However, further investigation has shown that Ras-Ral-
GEF-Ral signaling in humans dominated in driving Ras
mediated progression and metastasis [36,37]. We
obtained similar results when investigating Ras-down-
stream pathways participation in metastasis promotion
using HET-SR model [18]. We have shown that Ral-
GEF-Ral branch was the major contributor to the high
metastatic phenotype among three main Ha-Ras-depen-
dent signaling cascades.
RalA and RalB constitute a subfamily of proteins
within Ras superfamily of small G-proteins. Recent stu-
dies indicated that Ral proteins are involved in tumori-
genesis and cancer progression. There is still little data
regarding comparison of individual contribution of RalA
and RalB proteins in stimulation of metastasis.
Here we compared individual impact of RalA and
RalB activation on stimulation of tumor growth and
metastasis and estimated effect of simultaneous RalA
and RalB overexpression on these properties. We also
studied effect of Ral proteins on modulation of various
cell growth characteristics in vitro. For this purpose we
generated HET-SR variants with stable expression of
constitutively active forms of RalA and RalB. SMA
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neous injection revealed that both RalA and RalB
increased SMA but RalB was much more potent in sti-
mulation of lung metastasis.
These results are consistent with the idea that RalA
and RalB contribute to different aspects of tumorigen-
esis. Earlier, it was suggested that RalA was essential for
anchorage-independent growth of transformed cells
while RalB was responsible for tumor cell-autonomous
survival [6,14,19,20]. Data published later proposed the
mechanisms of RalB anti-apoptotic action through acti-
vation of RalB/TBK1 signaling pathway [38,39]. More-
over, Lim et al. showed that RalA knockdown reduced
tumorigenic growth of transformed cells (pancreatic
cancer cell lines) while RalB inhibition decreased inva-
sion and experimental metastasis [15]. Noteworthy, in
this study metastatic activity was assessed after intrave-
nous injection, thus reflecting later steps of cancer pro-
gression, i.e.: ability of cells to survive in circulation and
to form secondary focuses. Data presented here give evi-
dence that RalB, significantly more than RalA, stimulates
formation of lung metastases after subcutaneous
injection.
Further we searched for in vitro RalA- and RalB-
dependent alterations in cell properties associated with
acquisition of aggressive in vivo phenotype. Study of
growth dynamics didn’t show significant changes in pro-
liferation of RalA- and RalB-expressing HET-SR var-
iants. At the same time both RalA and RalB stimulated
wound healing as well as Cyclin D1 expression. These
results are in concordance with suggested role of Ral
proteins in cell motility stimulation [40].
Clonogenicity analysis revealed significant Ral-depen-
dent increase in size but not in number of formed colo-
nies. This effect was more pronounced in RalB than in
RalA expressing cells. We can speculate that better
adaptation to growth under conditions of rare cell den-
sity could reflect abilities to form micrometastases at
distant sites.
Results on invasion through Matrigel-coated chambers
correlated with SMA of HET-SR-Ral derivatives: Ral-
expressing cells were more invasive compared to corre-
sponding controls. At the same time, HET-SR-RalB cells
were more aggressive than HET-SR-RalA. This result
corresponds with mentioned above data on RalB deple-
tion dependent decrease of invasion and experimental
metastasis [15]. Invasion assay combines two processes:
proteolytic degradation of matrigel barrier and chemo-
tactic movement on serum gradient. Study of proteolytic
activity in conditioned media revealed uPA and MMP-1
stimulation only by active RalA. Therefore, RalB depen-
dent gain of invasion could not be explained by contri-
bution of studied proteinases. At the same time we
found that RalB stimulated migration on serum gradient
in uncoated chambers more than RalA. This result
shows that different invasion capacity demonstrated by
studied cells could be defined by chemotactic movement
rather than by activity of studied proteases. It could be a
result of RalB-dependent changes in growth-factor- or
chemokine-receptors regulation or downstream signal-
ing [41].
We also examined some Ral-associated proteins that
could serve as potential markers of high metastatic phe-
notype. Several studies suggest that tumor cells arriving
in target organ may roll on activated endothelium before
being able to arrest and proliferate [42,43]. It was pre-
viously shown that cell surface molecule CD24
expressed on tumor cells can support rolling on P-selec-
tin and thus CD24-P-selectin pathway may be an impor-
tant element in recruiting tumor cells to target organs
[15,44]. CD24 has been shown to be RalA-regulated in a
model of bladder cancer-derived cell lines [22]. We con-
firmed that RalA, but not RalB, upregulated CD24
expression which could contribute to RalA-mediated
increase of SMA.
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Figure 5 Among three main RalB effectors, PLD1 is essential
for HET-SR-RalB high metastatic phenotype. (a) Western blot
analysis was used to confirm expression of exogenous RalB G23V
effector mutants: ΔN11, D49N and D49E (blocking interaction with
PLD1, RalBP1 and exocyst complex respectively). (b) SMA test of
HET-SR cells expressing active RalB mutants. Activated RalB as well
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significant increase of SMA compared to the control (empty vector
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abrogation of activated RalB-dependent SMA stimulation.
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nalosome assembly. Alterations of Cav-1 expression in
different tumor types are associated with aggressive
behavior of cell lines and are proposed to be a prognos-
tic marker for some human malignancies (for review see
[27]). It was shown that Cav-1 could modulate activity
and expression of several proteins including RalA [27].
We revealed that expression of active RalB, opposite to
RalA, lead to decreased Cav-1 expression. Thus, we pro-
pose that a feedback loop can exist between Ral proteins
and Cav-1, giving additional level of complexity to this
branch of signaling.
We also checked whether Ral proteins could influence
MAPK signaling cascades in studied model. It was pre-
viously shown that Ral proteins could potentiate JNK1
and p38 activation [45-47]. Here we revealed that both
RalA and RalB activity induced JNK1 phosphorylation,
but we didn’t find significant changes in ERK1/2 or p38
activation.
In order to define RalB downstream partners in
metastasis stimulation, we used effector loop mutants
that abrogated interactions with certain effectors. We
studied the SMA-stimulating activity of three RalB effec-
tor mutants blocking interactions with PLD1 (ΔN11),
RalBP1 (D49N) and exocyst complex (D49E). RalB
ΔN11 mutant was the only one incapable to stimulate
spontaneous metastasis. So, we propose that interaction
with PLD1 is crucial for RalB-dependent lung metas-
tases formation. PLD1 is a well-known second-messen-
ger producer that regulates membrane traffic,
cytoskeletal reorganization and cell survival. Its activity
was elevated in some human tumors [48]. High levels of
PLD1 activity have been shown in T24 bladder and
Calu-1 lung cancer cells that harbor mutations in H-Ras
and K-Ras, respectively. The PLD1 activity in these cells
provided a survival signal that prevented apoptosis in
the conditions of serum starvation [49,50]. PLD1 activity
can also regulate growth factor receptor endocytosis
[51]. We suppose that RalB-PLD1 mediated influence
on growth factors signaling is important for RalB-depen-
dent chemotactic movement and stimulation of SMA.
Based on the assumption that RalA and RalB have
nonoverlapping functions, we checked the hypothesis
that simultaneous RalA and RalB activation may have
cumulative effect on SMA. Surprisingly, we found that
RalB expression did not strengthen the RalA-mediated
increase of SMA. Moreover, simultaneous expression of
both Ral proteins resulted in less level of SMA com-
pared to that of RalB alone expressing cells. That might
be a result of RalA-PLD interaction which could seques-
ter this effector from RalB. Future studies of RalA and
RalB in carcinogenesis and the specificity of their inter-
actions with effectors would hopefully open further
opportunities for target drug development.
Conclusion
Results presented here first time show that RalB activa-
tion significantly more than RalA stimulates lung metas-
tasis after subcutaneous injection of transformed cells
into immunocompetent animals. This property corre-
lates with the ability of RalB to stimulate in vitro inva-
sion and directed chemotactic cell movement. We also
found that among three main RalB effectors (RalBP1,
exocyst complex and PLD1) interaction with PLD1 is
essential for the acquisition of RalB-dependent high
metastatic cell phenotype. Besides, we hope to be the
first to study the effect of simultaneous RalA/RalB
expression on cell metastatic potential. We also pre-
sented here the data concerning effect of RalA and RalB
on expression, phosphorylation status and activity of
various key proteins known to be involved in tumor
progression and metastasis. We suppose that our find-
ings contribute to the identification of molecular
mechanisms of metastasis and tumor progression.
Methods
Cell cultures and plasmids
GP-293 line was purchased from Clontech; HET-SR
(Rous sarcoma virus-transformed hamster embryo fibro-
blasts) cell line was kindly provided by Dr G.I. Deichman
[32], Carcinogenesis Institute, Moscow). All cell lines
were maintained in Dulbecco’s modified Eagle’sm e d i u m
with 10% fetal bovine serum (FBS; PAA Laboratories) in
37°C and 5% CO2 atmosphere. pRK5-RalA-G23V vector
and pSRa-RalB-G23V vectors (D49N, D49E, ΔN11) were
granted by Dr Jacques Camonis (Transduction du signal
et oncogenèse, Institut Curie, France). RalA sequence
was cloned into pLXSN retroviral vector by EcoRI and
XhoI sites; RalB encoding sequences were cloned in
pBabe-puro retroviral vector by BamHI and SalI. All con-
structs were verified by sequencing.
Production of stable cell lines
GP-293 cells were cotransfected with retroviral vectors
and pVSVG (Clontech) using Lipofectamine 2000 (Invi-
trogen) according to manufacturer’s protocol. 48 and 72
hours after transfection, virus-containing media was
applied to 50% confluent HET-SR cells in the presence
of 8 mcg/ml Polybrene (Sigma). Infected cells were
selected in 1.1 mg/ml G418-containing medium (Calbio-
chem) for pLXSN-infected cells for 14 days and in 3.5
mcg/ml puromycin-containing medium (Sigma) for
pBabe-puro infected cells for 7 days.
Analysis of tumor growth and spontaneous metastatic
activity (SMA) in vivo
2×1 0
4 cells in 0.5 ml of serum-free media were
injected subcutaneously in adult (10 weeks old) Syrian
hamsters (Mesocricetus auratus). Two months after
Rybko et al. Cancer Cell International 2011, 11:22
http://www.cancerci.com/content/11/1/22
Page 9 of 12injection, animals were sacrificed and lungs were collected.
Lungs were fixed in alcoholic formalin (10% of formalin
and 63% of ethanol). Paraffin-embedded tissues were step-
sectioned and stained with hematoxylin-eosin. Metastatic
tumor nodules in the lungs were counted microscopically
(72 sections per lung per hamster of ten hamsters per
group). SMA test for each cell line was performed twice.
Tumor growth was hand measured every 7 days.
The animal experimental protocols were approved by
the Committee for Ethics of Animal Experimentation
and the experiments were conducted in accordance with
the Guidelines for Animal Experiments in N.N. Blokhin
Cancer Research Center.
Preparation of conditioned media
4×1 0
5 cells were seeded in 6-well plates in full med-
ium. 18 hours later the medium was replaced with 1 ml
of serum-free DMEM and 24 hours later the medium
was centrifuged 10 minutes at 3000 g. The supernatant
was stored at -70°C and used for zymographic analysis.
Gelatin zymography was performed using 8% SDS-
PAGE gels, containing 0.2% gelatin (AppliChem). Condi-
tioned media samples were mixed 1:1 with zymography
sample buffer (0.125 M Tris-HCl pH 6.8; 20% glycerol;
4% SDS; 0.05% Bromophenol blue (Sigma)) and loaded
to the gels. After electrophoresis gels were incubated 30
minutes in 2.5% Triton X-100 at room temperature, 30
minutes in collagenase activation buffer (50 mM Tris-
HCl, pH 7.4, containing 6.6 mM CaCl2 and 200 mM
NaCl and 0.2% Brij-35) at room temperature and 4
hours in the same buffer at 37°C. After incubation gels
were stained with Coomassie Blue G-250 solution (20%
EtOH; 0.08% Coomassie G-250 (Bio-Rad); 1.6% phos-
phoric acid; 8% ammonium sulfate) overnight. Gelati-
nases activity was visualized as distinct bands indicating
proteolysis of the substrate.
Casein-plasminogen zymography was performed in
10% SDS- PAGE gels containing plasminogen (0.04 u/
ml, Sigma) and a-casein (2 mg/ml, Fluka). Electrophore-
tic separation of the conditioned media samples was
performed as described for gelatin zymography. Gels
were incubated 30 minutes with Triton X-100 (2.5%) at
room temperature, 30 minutes in distilled water at
room temperature, and 4 hours in uPA activation buffer
(25 mM Tris-HCl, pH 7.4, containing 3.3 mM CaCl2
and 100 mM NaCl) at 37°C. Caseinolytic bands were
visualized after Coomassie Blue G-250 solution staining.
Western-blot analysis and antibodies
Western blot analysis was proceeded as described pre-
viously [18]. Following primary antibodies were used:
anti-RalA (Upstate, Millipore), anti-RalB (Upstate, Milli-
pore), anti-Cyclin D1 (Sigma), anti-Caveolin-1 (Sigma);
anti-phospho-JNK1 (T183, Abcam), anti-JNK1 (Abcam),
anti-phospho-p38 (Y182 and T180, Abcam), anti-p38
(Abcam), anti-ERK1/2 (Cell Signalling), anti-phospho-
ERK1/2 (T202 and T204, Cell Signalling), anti-b-actin
(Abcam); anti-CD24 (Chemicon). Images of obtained
blots were captured using Kodak GelLogic 2200 Imaging
system and processed using Kodak Molecular Imaging
Software SE ver. 5.0.1.27
Proliferation assay
For proliferation dynamics analysis 5 × 10
3 cells were
seeded in triplicate on 96-well tissue culture plates.
MTT-analysis was conducted daily. Cell proliferation
was analyzed using 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT, Sigma). In brief,
0.5 mcg/ml MTT in media was added to every plate for
1 hour, then cells were lysed using acidic isopropanol
and OD data was measured at 595 nm using microplate
reader Benchmark Plus, BioRad. Cell doubling time was
calculated and graphs were plotted using GraphPad
Prizm software, ver. 5.02.
Wound Healing Assay
3×1 0
5 cells were seeded on a 6-well plate and 24 hours
later “wounds” were scratched with a 1000-mcl pipette
tip, washed with medium and photographed with a digi-
tal camera DP71 using inverted microscope Olympus
IX-51 (10 × objective lens). Matched pair-marked
wound regions were photographed again after 24 hours.
The width of the wound at the same position was mea-
sured repeatedly by using ImageJ 1.42 I software (6 mea-
sures per well and 3 wells per sample, 18 total
measurement points per cell line). Migration index was
calculated by following formula: % Migration = (the
width of initial wound-the width of wound after 24 h) ×
100/the width of initial wound.
In vitro invasion assay
Invasive ability of cells was measured with a QCM Cell
Invasion Colorimetric Assay (Millipore) according to the
manufacturer’s protocol. Briefly, cells (2 × 10
5)i n0 . 5m l
of serum-free DMEM were seeded into the upper cham-
ber with Matrigel-coated membrane. 0.75 ml of DMEM
containing 10% fetal bovine serum was added into the
lower chamber. After 18 hours incubating at 37°C, mem-
branes were collected and noninvading cells were
removed from the upper surface of the membrane using
a cotton swab. Membranes were stained with 0.1% crystal
violet, and photographed with digital camera DP71 using
inverted microscope Olympus IX-51 with 10 × objective.
Transwell Migration Assay
Corning Costar Transwell plates (8 μm) were pretreated
according to the manufacturer’s protocol. Directed moti-
lity assay was performed in uncoated chambers in
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10
5 cells were seeded in the upper chambers. After incu-
bating (18 hours at 37°C), membranes were collected
and noninvaded cells were removed from the upper
chamber using cotton swab, stained with 0.1% crystal
violet and photographed with digital camera DP71 using
inverted microscope Olympus IX-51 with 10 × objective.
Clonogenicity Assay
2×1 0
2 cells were seeded on 6-cm Petri dish. 6 days
later formed colonies were fixed with ethanol and
stained with crystal violet. Pictures of Petri dishes were
taken by compact camera and colonies number and size
were measured using ImageJ software.
Statistical analysis
All cell culture experiments were held in triplicate.
Graph data represent the mean ± standard error calcu-
lated from indicated number of independent experi-
ments. Differences between two groups were assessed
using Mann-Whitney U test. Simultaneous comparison
of three or more groups was performed by using Krus-
kal-Wallis one-way analysis of variance followed Dunns
post-test to compare with control group, if it was neces-
sary. Quantification of Western blot data was made by
Molecular Imaging Research ver. 5.01 software by
Kodak. Results were analyzed and graphs built using
GraphPad Prizm ver. 5.02 by GraphPad Software.
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